Jacek Kiljański

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

Baptist Gallwitz, Juan M. Sánchez‐Guzmán, Francesco Dotta et al. · The Lancet · 2012 · 159 citations

Medicine, Internal Medicine, Pharmacotherapy +15

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

Rafael Simó, Bruno Guerci, Guntram Schernthaner et al. · Cardiovascular Diabetology · 2015 · 48 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes

Magaly Perez‐Nieves, Kristina S. Boye, Jacek Kiljański et al. · Diabetes Therapy · 2018 · 28 citations · Full text

Pharmacy, Endocrinology, Pharmacoeconomics +17

Should Graves' Disease be Considered a Collagen Disorder of the Thyroid, Skeletal Muscle and Connective Tissue?

Jacek Kiljański, Vicki L. Nebes, Irene Stachura et al. · Hormone and Metabolic Research · 1995 · 26 citations

Medicine, Endocrinology, Ophthalmology +14

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study

Matthew Reaney, Chantal Mathieu, Claes‐Göran Östenson et al. · Health and Quality of Life Outcomes · 2013 · 23 citations · Full text

Medicine, Endocrinology, Internal Medicine +17